Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-cash Items (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Non-cash Items for 11 consecutive years, with $11.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items rose 23.13% year-over-year to $11.8 million, compared with a TTM value of $11.8 million through Dec 2025, up 23.13%, and an annual FY2025 reading of $11.8 million, up 2966.75% over the prior year.
  • Non-cash Items was $11.8 million for Q4 2025 at Heron Therapeutics, up from $9.6 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $13.6 million in Q4 2022 and bottomed at $1.7 million in Q4 2021.
  • Average Non-cash Items over 5 years is $9.6 million, with a median of $11.4 million recorded in 2023.
  • The sharpest move saw Non-cash Items plummeted 83.39% in 2021, then skyrocketed 702.94% in 2022.
  • Year by year, Non-cash Items stood at $1.7 million in 2021, then surged by 702.94% to $13.6 million in 2022, then dropped by 16.56% to $11.4 million in 2023, then dropped by 15.81% to $9.6 million in 2024, then rose by 23.13% to $11.8 million in 2025.
  • Business Quant data shows Non-cash Items for HRTX at $11.8 million in Q4 2025, $9.6 million in Q4 2024, and $11.4 million in Q4 2023.